TGF-β / Smad Signaling

The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B5954 Dasatinib MonohydrateTarget: PDGFR|c-Kit|Bcr-Abl|SrcSummary: Inhibitor of ABL, SRC, KIT, PDGFR, and other tyrosine kinases. -
B7807 Netarsudil (AR-13324)Target: ROCKSummary: ROCK inhibitor -
B1404 DCC-2036 (Rebastinib)Target: FLT3|Bcr-Abl|Tie-2|KDRSummary: Bcr-Abl inhibitor -
B5863 LX7101 HCLSummary: Dual LIM-kinase and ROCK inhibitor -
B3709 Midostaurin (PKC412)Target: PKC|PKA|KDR|Flk1|PPK|c-Syk|CDK1/CyclinBSummary: PKC inhibitor -
B1011 Bafetinib (INNO-406)2 CitationSummary: Bcr-Abl/Lyn tyrosine kinase inhibitor -
C3656 ALK5 Inhibitor II (hydrochloride)Summary: ALK5 inhibitor -
B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor -
B3392 GSK269962ATarget: ROCK|RSK|MSKSummary: ROCK inhibitor -
A8812 PD173955Target: Bcr-Abl|SrcSummary: Dual Src/Abl kinase inhibitor, ATP-competitive,
